Literature DB >> 11592778

Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.

E Song1, J Chen, N Ouyang, F Su, M Wang, U Heemann.   

Abstract

Expression of membrane-bound Fas ligand (mFasL) on colon cancer cells serves as a potential mechanism to inhibit host immune function by inducing apoptosis of host lymphocytes. Membrane-bound FasL can be cleaved and released as a soluble mediator (sFasL), which may spread the apoptosis induction effect. Our study examined whether colon adenocarcinoma cells release sFasL, and induce apoptosis of host lymphocytes without direct cell-cell contact. In 12 consecutive patients with colon adenocarcinoma mFasL was identified in the tumours, sFasL was measured in the sera and apoptosis identified in tumour-infiltrating and peripheral blood lymphocytes. To analyse the function of sFasL, colon cancer cells were primarily cultured; sFasL was isolated from supernatants, measured, incubated with Fas-bearing Jurkat cells, and the resulting apoptosis was analysed. Serum levels of sFasL were significantly elevated in all colon cancer patients with mFasL expression in tumour tissues (n = 8). In these patients, the number of apoptotic lymphocytes was significantly increased within tumour and peripheral blood. Furthermore, sFasL was present in the corresponding supernatants and induced apoptosis of Jurkat cells in a dose-dependent manner. These findings suggest that mFasL-positive colon cancer cells release sFasL, and thus may induce apoptosis of host lymphocytes as a potential mechanism for immune evasion. Copyright 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592778      PMCID: PMC2375090          DOI: 10.1054/bjoc.2001.2042

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  [Increased serum soluble Fas ligand in hyperthyroid Graves' disease].

Authors:  K Takeda; E Ohara; T Kaneda; K Hashimoto; M Sasaki
Journal:  Rinsho Byori       Date:  1999-10

2.  Fas ligand expression in esophageal carcinomas and their lymph node metastases.

Authors:  M Younes; M R Schwartz; A Ertan; D Finnie; A Younes
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

3.  Soluble Fas ligand expression in the ocular fluids of uveitis patients.

Authors:  C Sotozono; Y Sano; T Suzuki; R Tada; T Ikeda; S Nagata; S Kinoshita
Journal:  Curr Eye Res       Date:  2000-01       Impact factor: 2.424

4.  Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; D Roche; J Kelly; J K Collins; F Shanahan
Journal:  J Pathol       Date:  1998-11       Impact factor: 7.996

5.  Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS).

Authors:  G Matute-Bello; W C Liles; K P Steinberg; P A Kiener; S Mongovin; E Y Chi; M Jonas; T R Martin
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

6.  Liver dysfunction due to apoptosis in a patient with systemic lupus erythematosus.

Authors:  M Mukai; T Bohgaki; A Notoya; M Kohno; M Tateno; S Kobayashi
Journal:  Lupus       Date:  2000       Impact factor: 2.911

7.  Increased levels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV-infected patients.

Authors:  B Sporer; U Koedel; F D Goebel; H W Pfister
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

8.  Malaria infection induces rapid elevation of the soluble Fas ligand level in serum and subsequent T lymphocytopenia: possible factors responsible for the differences in susceptibility of two species of Macaca monkeys to Plasmodium coatneyi infection.

Authors:  J Matsumoto; S Kawai; K Terao; M Kirinoki; Y Yasutomi; M Aikawa; H Matsuda
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

9.  Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion.

Authors:  J S Luo; R Kammerer; S von Kleist
Journal:  Tumour Biol       Date:  2000 Jan-Feb

10.  Kupffer cells of cirrhotic rat livers sensitize colon cancer cells to Fas-mediated apoptosis.

Authors:  E Song; J Chen; N Ouyang; M Wang; M S Exton; U Heemann
Journal:  Br J Cancer       Date:  2001-05-04       Impact factor: 7.640

View more
  23 in total

Review 1.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

2.  Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients.

Authors:  Martha Stathaki; Athanasios Armakolas; Andreas Dimakakos; Loukas Kaklamanis; Ioannis Vlachos; Manoussos M Konstantoulakis; George Zografos; Michael Koutsilieris
Journal:  Mol Med       Date:  2014-03-18       Impact factor: 6.354

3.  Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.

Authors:  Kebin Liu
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

Review 4.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

5.  FasL gene knock-down therapy enhances the antiglioma immune response.

Authors:  Timothy Jansen; Betty Tyler; Joseph L Mankowski; Violette Renard Recinos; Gustavo Pradilla; Federico Legnani; John Laterra; Alessandro Olivi
Journal:  Neuro Oncol       Date:  2010-01-29       Impact factor: 12.300

6.  The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.

Authors:  Ramazan Yildiz; Mustafa Benekli; Suleyman Buyukberber; Ali Osman Kaya; Banu Ozturk; Emel Yaman; Veli Berk; Ugur Coskun; Deniz Yamac; Banu Sancak; Aytug Uner
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-13       Impact factor: 4.553

Review 7.  Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review.

Authors:  G Peach; C Kim; E Zacharakis; S Purkayastha; P Ziprin
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

8.  Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.

Authors:  Taofeek K Owonikoko; Mohammad S Hossain; Chandar Bhimani; Zhengjia Chen; Sungjin Kim; Suresh S Ramalingam; Shi-Yong Sun; Dong M Shin; Edmund K Waller; Fadlo R Khuri
Journal:  Cancer       Date:  2013-01-22       Impact factor: 6.860

9.  Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.

Authors:  Gaosi Xu; Jiangguo Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-07       Impact factor: 4.553

10.  Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients.

Authors:  Hiroaki Saito; Seigo Takaya; Tomohiro Osaki; Masahide Ikeguchi
Journal:  Gastric Cancer       Date:  2012-11-22       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.